NanoVision Diagnostics

TECHNOLOGY

The NanoVision Diagnostics system assesses molecular changes in nuclear DNA from a standard biopsy slide. The genetic and epigenetic changes that induce cancer also change chromatin structure. NanoVision Diagnostics has developed a novel method of measuring changes in chromatin structure.  Chromatin structural changes have been shown to correlate with cancer in multiple clinical studies.

The NanoVision Diagnostics system is 1000 times more sensitive than an optical microscope, allowing it to measure molecular scale changes in DNA structure. Multiple clinical studies demonstrate these changes correlate with cancer in multiple organ systems. The NanoVision Diagnostics system generates an objective graphical output and numerical score to guide physicians in cancer treatment decisions.

UNIQUE ADVANTAGES

Since patients with positive optical biomarkers are more likely to progress to cancer, the NanoVision Diagnostics system:

Saves Lives and Saves Money by:

Helps Prevent Future Cancers by:

CLINICAL VALIDATION

The NanoVision Diagnostics system has been validated in 11 clinical studies involving over 1000 patients, in multiple digestive and gynecological cancers – all demonstrated high accuracy. Click here for more information.

INVENTOR

Yang Liu PhD, Inventor - Dr. Liu is Assistant Professor of Medicine and Bioengineering at the University of Pittsburgh. Her research focuses on novel optical technologies for cancer diagnosis, surveillance and prognosis. Dr. Liu has 8 US/International patents, 50 peer-reviewed journal publications and over 50 conference presentations. Learn more about Dr. Liu.